A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether multiple dose administration is safe and well tolerated in patients with mild to moderate Alzheimer's Disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Males or females of non childbearing potential, age > or = 50.

• Diagnosis of probable Alzheimer's disease, consistent with criteria from both:

• National Institute of Neurological and Communicable Disease and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA).

• Diagnostic and Statistical Manual of Mental Disorders (DSM IV).

• Mini-mental status exam score of 16-26 inclusive.

• Rosen-Modified Hachinski Ischemia Score of < or = 4.

Exclusion Criteria:

• Diagnosis or history of other demential or neurodegenerative disorders.

• Diagnosis or history of clinically significant cerebrovascular disease.

• Specific findings on magnetic resonance imaging (MRI); cortical infarct, micro hemorrhage, multiple white matter lacunes, extensive white matter abnormalities.

• History of autoimmune disorders.

• History of allergic or anaphylactic reactions.